An unconventional anti-apoptotic function of HIF-1α under hypoxia involves ERKregulated association of its C-terminal domain with outer mitochondrial membrane proteins. 
Introduction
Exposure to low oxygen conditions (hypoxia) triggers changes in gene expression mediated by the hypoxia-inducible factors (HIFs) (Semenza, 2012) . Gene activation by HIFs results in metabolic reprogramming stimulates angiogenesis and impacts proliferation of cells subjected to hypoxia. Adaptation of cancer cells to the hypoxic microenvironment of solid tumors as well as survival of normal cells in ischemic tissues, therefore, depends on the activation of HIFs (Keith et al., 2012) . HIFs are composed of oxygen-regulated HIFα subunits and HIFβ (ARNT). Expression of HIF-1α, the most studied and widely expressed HIFα isoform, is continuous but, in the presence of physiological oxygen concentration, the protein fails to accumulate as it is degraded by the proteasome following its hydroxylation by oxygen-dependent PHDs and its polyubiquitination by a pVHL-containing E3 ligase complex (Schofield and Ratcliffe, 2005) . When oxygen levels drop, HIF-1α very rapidly accumulates as a result of inhibition of hydroxylation and subsequent stabilization. HIF-1α is then transported into the nucleus, forms a heterodimer with ARNT, binds to hypoxia-response DNA elements (HREs) and promotes expression of hypoxia target genes.
In addition to oxygen-dependent stabilization of HIF-1α, HIF-1 is also controlled by mechanisms not directly involving oxygen but implicating oncogenic signaling pathways, protein interactions and diverse modifications (Dengler et al., 2014) . Direct phosphorylation by kinases such as GSK3, PLK3, CDK1 and ATM (Kietzmann et al., 2016) affect HIF-1α protein stability while others, such as ERK1/2 (Mylonis et al., 2008) and CK1δ (Kalousi et al., 2010) , control its activity by affecting nuclear accumulation or heterodimerization with ARNT, respectively. More specifically, phosphorylation of HIF-1α at Ser641/643 by ERK masks an adjacent CRM1-dependent nuclear export signal (NES) and inhibits HIF-1α nuclear export, thereby increasing its nuclear concentration and transactivation ability (Mylonis et al., 2008) .
stimulates mitochondrial autophagy and up-regulates the expression of anti-apoptotic genes of the Bcl-2 family (Sendoel and Hengartner, 2014) , thereby also increasing resistance of cancer cells to chemotherapy (Wilson and Hay, 2011) .
Hypoxia also affects mitochondrial-mediated apoptosis by interfering with the function of outer mitochondrial membrane (OMM) proteins. Hypoxia stimulates the expression of hexokinase II (HK-II), a hexokinase isoform that is upregulated in various tumors and is associated with higher tumor grade and mortality (Roberts and Miyamoto, 2015) . HK-II binds to the OMM via its interaction with the voltage-dependent anion channel 1 (VDAC1), the major porin of OMM. Mitochondrial HK-II not only contributes to the glycolytic phenotype of cancer cells by coupling mitochondrial production of ATP to glucose phosphorylation (the first step of glycolysis) but also prevents apoptosis by inhibiting binding of pro-apoptotic factors to the OMM and blocking release of cytochrome c, the intrinsic trigger of caspase activation.
VDAC1 itself is also involved in apoptotic signaling by interacting with Bcl-2 family proteins and by affecting OMM permeabilization and escape of apoptogenic proteins (Shoshan-Barmatz et al., 2015) . In several different cancer cell lines, hypoxia triggers proteolytic processing of VDAC1 to produce a C-terminally truncated active form called VDAC1-ΔC (Brahimi-Horn et al., 2012; Brahimi-Horn et al., 2015) .
Production of VDAC1-ΔC depends on HIF-1 and HK-II and is associated with enlarged mitochondria and increased resistance to drug-induced apoptosis. Finally, VDAC1 also interacts with mortalin, also known as GRP75 (Schwarzer et al., 2002; Szabadkai et al., 2006) . Μortalin resides mainly on the OMM and its overexpression is associated with chemotherapy resistance and cancer progression and metastasis (Lee, 2014) .
The involvement of HIF-1 in regulation of apoptosis has so far been assumed to be indirect through transcriptional activation of genes encoding pro-or anti-apoptotic factors. We demonstrate in this work an unconventional, non-genomic role of HIF-1α as an ERK-regulated effector of apoptosis through its association with mortalin, VDAC1
and HK-II on the mitochondrial surface.
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Results
ERK-controlled interaction of HIF-1α with mortalin
To identify phosphorylation-dependent interactions of HIF-1α, GST-tagged forms of its ERK-targeted domain (ETD, amino acids 616-658) carrying either phospho-deficient (ETD-SA: Ser641/643Ala) or phosphomimetic (ETD-SE: Ser641Glu) mutations were used as baits in pull-down assays with total HeLa cell protein extracts. A single 75 kDa protein could be detected associated specifically with ETD-SA (Fig. 1A) and was identified by mass-spectrometric analysis (Table S1 ) as mortalin. Immunoblotting confirmed the identity of mortalin (Fig. 1A) while immunoprecipitation of endogenous HIF-1α demonstrated its interaction with mortalin under hypoxia (Fig. 1B) . This interaction was enhanced when ERK activation was blocked by the selective MEK inhibitor U0126, which significantly reduced the overall phosphorylation of HIF-1α at serine residues (Fig. S1A ), thus confirming that mortalin binds preferably to HIF-1α lacking ERK-mediated modifications (hence referred to as unmodified HIF-1α). In the reverse experiment, immunoprecipitation of mortalin confirmed its association with unmodified HIF-1α (Fig. S1B) and, in addition, showed its inability to associate with HIF-2α (Fig. S1C) , as suggested by the uniqueness of the ETD amino acid sequence in HIF-1α.
Treatment with U0126 also caused translocation of HIF-1α outside the nucleus (Fig. 1C) , strong inhibition of its transcriptional activity (Fig. 1E) and reduction in the expression of the HIF-1-target genes VEGF, BNIP3 and NDRG1 (Fig. 1F) . Furthermore, non-nuclear HIF-1α largely co-localized with mortalin (Fig. 1C) . The physical interaction between HIF-1α and mortalin and its stimulation by U0126 were also confirmed by the in situ proximity ligation assay (in situ PLA; Fig. 1D ). HIF-1α/mortalin complexes could be already detected under hypoxia in the absence of U0126 and their number significantly increased when HIF-1α phosphorylation by ERK was inhibited.
ERK-controlled and mortalin-mediated association of HIF-1α with the mitochondrial surface
The physical association of HIF-1α with mortalin suggested that unmodified HIF-1α might also associate with mitochondria. Indeed, hypoxia-induced endogenous HIF-1α lost its predominant nuclear location and co-localized to significant extent with Journal of Cell Science • Advance article mitochondria in HeLa cells treated with U0126 and monitored by either optical ( Fig. 2A) or confocal laser (Fig. S1D ) microscopy. To exclude the possibility that this "unconventional" localization of HIF-1α was caused by non-specific effects of U0126, hypoxia-induced HIF-1α was localized in HeLa cells cultured in the absence of FBS, a condition that inactivates the MAPK-ERK pathway. Serum withdrawal indeed caused inhibition of expression of VEGF, P4HA1-1, BNIP3 and NDRG1, four HIF-1 target genes ( Fig. 2B) , cytoplasmic translocation of HIF-1α and its extensive co-localization with mitochondria ( Fig. 2C) . The mitochondrial localization of HIF-1α under serum deprivation was reversed to nuclear when cells were treated with Leptomycin B (LMB; Fig. 2C ), a potent CRM1 inhibitor, suggesting that, targeting of HIF-1α to mitochondria was due to stimulation of HIF-1α nuclear export following ERK inactivation. To confirm the results in a non-cancerous cell line, endogenous HIF-1α was also localized in primary rabbit tracheal smooth muscle (RTSM) cells. Under hypoxia, HIF-1α was predominantly nuclear but a minor fraction was readily detectable in cytoplasmic structures (Fig. 2D ).
However, upon serum withdrawal, a large pool of HIF-1α translocated to the cytoplasm and co-localized extensively with mitochondria showing that mitochondrial localization of unmodified HIF-1α is not a unique property of cancer cells. In both HeLa and RTSM cell lines, co-localization of HIF-1α with mitochondria under ERK inactivation conditions occured in all cells (Fig. S2) . Furthermore, visual, quantitative and statistical evaluation ( Fig. S2) , clearly showed that HIF-1α co-localization with mitochondria was non-random, increased significantly after ERK inactivation and involved a major fraction (close to 50%) of the total cellular HIF-1α population.
To independently verify the ERK-controlled mitochondrial localization of HIF-1α
we examined the involvement of its known ERK-modification sites at Ser641/643 by analysing under normoxia HeLa cells not expressing endogenous HIF-1α but overexpressing GFP-tagged wild-type HIF-1α or its HIF-1α-SA mutant lacking the ERK sites. Wild-type GFP-HIF-1α was predominantly nuclear but mutant GFP-HIF-1α-SA was excluded from the nucleus and largely co-localized with mitochondria ( Fig. 3A and Fig. S1E ). In agreement, treatment with U0126 triggered significant translocation of wild-type GFP-HIF-1α out of the nucleus and extensive co-localization with mitochondria under normoxia (Fig. 3A) , suggesting that distribution of HIF-1α between nucleus and mitochondria is a process controlled predominantly by ERK and does not Journal of Cell Science • Advance article require any additional hypoxia-induced mechanisms apart of HIF-1α stabilization. Same results were obtained when Flag-tagged forms of ETD were examined (Fig. 3B ), further suggesting that unmodified ETD, the part of HIF-1 that interacts with mortalin, mediates hypoxia-independent but ERK-dependent targeting of HIF-1α to mitochondria. The mitochondrial localization of GFP-HIF-1α-SA under normoxia was also confirmed by confocal laser microscopy in a second unrelated cancer line, human hepatoma Huh7 cells (Fig. 3C ). When the same cells were grown under hypoxia, treatment with kaempferol, a dietary flavonoid that inhibits HIF-1α phosphorylation by ERK (Mylonis et al., 2010) caused translocation of endogenous HIF-1α outside the nucleus and significant colocalization with mitochondria ( Fig. 3D ) confirming again the results obtained with HeLa cells and U0126 (see Fig. 2A ). In contrast to the almost exclusive localization of GFP-HIF-1α-SA and Flag-ETD-SA outside the nucleus and in association with mitochondria, inhibition of ERK activation caused partial translocation of wild-type HIF-1α, which may be attributed to the significant but incomplete ERK inactivation (see (Table S2) showed that upon ERK inactivation, HIF-1α in the nuclear fraction was reduced by approximately 60%. At the same time, HIF-1α was increased more than 3-fold in the mitochondrial fraction and 2-fold in the cytosolic one.
These results are in agreement with the microscopic data and confirm that a relatively large fraction of nuclear HIF-1α migrates to the mitochondria when its phosphorylation by ERK is inhibited. to their antibodies at conditions that exposed Tom20, a component of the OMM, but left components of the mitochondrial intra-membrane space (cytochrome c) or matrix (hsp60) inaccessible ( Fig. 4C ). This suggests that HIF-1α associates through mortalin with the OMM. Significantly stronger induction of apoptosis under only combined treatment was also quantitatively documented by many-fold increase of caspase 3/7 activity in whole cell extracts (Fig. 5E ). These data show that under hypoxia ERK activation is required to protect from apoptosis when HIF-1α is depleted, while HIF-1α protects cells from apoptosis under ERK-inactivation conditions. Since these conditions inhibit HIF-1 activity, it is likely that protection is mainly provided by the unmodified, mitochondrial form of HIF-1α. To check this, the experiment was repeated but, instead of depleting HIF-1α, its association with mitochondria was disrupted by overexpressing Flag-tagged ETD-SA that would compete with endogenous unmodified HIF-1α for binding to mortalin and targeting to mitochondria ( 
ERK inactivation triggers apoptosis when HIF-1α is released from mitochondria
Mitochondrial HIF-1α protects from drug-induced apoptosis through its C-terminal domain
To verify the non-genomic anti-apoptotic function of HIF-1 by independent means, we used cytotoxic chemotherapeutic reagents, known to trigger apoptosis such as etoposide (Fig. 6G,H) .
Overexpression of Flag-ETD-SA that is targeted to mitochondria did not protect normoxic cells from etoposide-or doxorubicin-triggered apoptosis (Fig. 6C,I ) suggesting that association of ETD with mitochondria alone is not sufficient to inhibit apoptosis but protection from apoptosis requires the presence of full-length HIF-1α or, at least, an additional domain. To define which part of HIF-1α is responsible for the protective effect and to further confirm that this effect is not due a residual transcriptional function of HIF-1α leading to activation of anti-apoptotic genes, the experiments were repeated (Fig.   6D ,E,K,L) in cells expressing chimeric proteins composed of the Gal4-DNA binding domain (Gal4-DBD) fused to wild-type or mutant forms of the C-terminal part of HIF-1α
(HIF-1α-348-826). These proteins lack the N-terminal DNA binding and PAS domains but possess GAL4-dependent transactivation ability (Mylonis et al., 2006) . In this case, neither the wild-type nor the SE form of Gal4-DBD-HIF-1α-348-826 provided significant protection from etoposide-or doxorubicin-triggered apoptosis (Fig. 6E,L) , as expected by their lack of HRE-dependent transcriptional activity. In sharp contrast, the SA form increased levels of VDAC1-ΔC, reduced act. casp3 (Fig. 6D ,K, lane 7) and decreased caspase 3/7 activity (Fig. 6E,L) , thus showing that the anti-apoptotic function of unmodified HIF-1α resides in its C-terminal part and is independent of HRE-binding or heterodimerization with ARNT. Similar results were obtained after expression of GFPtagged wild-type or mutant forms of a shorter C-terminal domain of HIF-1α (Fig. 6F,M) showing that the observed effects are independent of the N-terminal tag and mapping the non-genomic anti-apoptotic function of HIF-1α to amino acids 575-826 comprising the inhibitory and C-terminally transactivation domains (ID and C-TAD, respectively).
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Mitochondrial HIF-1α associates with VDAC1 and HK-II
To address the mechanism underlying the anti-apoptotic function of mitochondrial HIF-1α, immunoprecipitates of HIF-1α from cytoplasmic (cytosol plus mitochondria) or nuclear extracts of cells grown under hypoxia (Fig. 7A , lanes 5,7) and treated with U0126
( Fig. 7A, lanes 6,8) were analyzed for the presence of proteins known to reside on the OMM and play a role in apoptosis. In addition to mortalin, HK-II associated with cytoplasmic but not nuclear HIF-1α (Fig. 7A , compare lane 5 with 7). Association of both proteins with HIF-1α became stronger upon U0126 treatment, which also revealed the presence of VDAC1 in the same cytoplasmic complexes (Fig. 7A, lane 6) , while under all conditions nuclear HIF-1α complexes contained only ARNT (Fig. 7A , lanes 7 & 8).
When mortalin was immunoprecipitated from cells grown under normoxia, it associated with VDAC1 (in agreement with previous observations, see Introduction) but did not interact detectably with HK-II (Fig. 7B, lanes 7-9) . Under hypoxia, the cytoplasmic mortalin complexes contained, in addition to VDAC1, HIF-1α and HK-II (Fig. 7C, lanes 7,8,9 ) and ERK inactivation strengthened the association of HIF-1α with the mortalin complex (Fig. 7C , compare lanes 8,9 with 7). Taken together, these data demonstrate association of HIF-1α with VDAC1 and HK-II, both regulating mitochondrial-mediated apoptosis. Furthermore, it is likely that mortalin links HIF-1α to VDAC1 while HIF-1α interacts directly with HK-II (since mortalin binds to VDAC1 but not to HK-II in the absence of HIF-1α) and, therefore, HIF-1α may facilitate HK-II recruitment in the VDAC1/mortalin/HIF-1α complex on the OMM.
Discussion
Our study reveals that HIF-1α can directly inhibit apoptosis by binding to proteins of the OMM. This role of HIF-1α is distinct from other known HIF-1α functions and several lines of evidence suggest that is independent of HIF-1α transcriptional activity but depends on ERK-mediated modification of Ser641/643 in the ETD of HIF-1α. To conclude, our data suggest that HIF-1α participates in the formation of a VDAC1-mortalin-HIF-1α-HK-II complex that stimulates production of anti-apoptotic VDAC1-ΔC, protects the integrity of ΔΨm, inhibits cytochrome c release and prevents caspase activation, thereby blocking induction of apoptosis and cell death under hypoxia.
As formation of this complex does not require hypoxia-dependent gene expression, it can be formed as soon as HIF-1α is stabilized and in the range of few minutes after the onset of hypoxia. Thus, the non-genomic function of HIF-1α revealed in this study may represent an "early" mechanism that operates when cells first encounter hypoxia and counteracts the ensuing immediate mitochondrial stress (e.g. increased production of ROS and reduced production of ATP) until the "late" HIF-dependent stimulation of adaptive gene expression kicks in and takes over. This "early" pro-survival mechanism mediated directly by HIF-1α may also explain the requirement of HIF-1α for acute phase (early window) ischemic preconditioning that protects against ischemia-reperfusion injury (Cai et al., 2008) , since the duration of the brief preconditioning ischemic episodes may be incompatible with de novo protein synthesis of survival factors encoded by HIF-1-target genes. In support of this hypothesis, hypoxic preconditioning (cycles of hypoxia and reoxygenation) of cultured rat cardiac myocytes was shown to cause increased recovery of HIF-1α in mitochondrial fractions, although the functional significance of this was not investigated (Rane et al., 2009 ).
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Protection by mitochondrial-associated HIF-1α may be especially important for quiescent or non-proliferating cells in which the MAPK-ERK signaling pathway is inactive (Fig. 7D,E) . Activation of the MAPK-ERK pathway leads to phosphorylation and subsequent inactivation of the key pro-apoptotic factor Bim (Ewings et al., 2007) , thus offering protection against apoptotic insults. Therefore, cells with suppressed ERK are likely to be more sensitive to apoptosis when exposed to low oxygen, which would create the need for fast HIF-1α-mediated assembly of a pro-survival complex on the OMM. On the other hand, cells with active ERK are more resistant to apoptosis but their rapid proliferation may create a greater need for up-regulation of metabolic genes mediated by nuclear and transcriptionally active HIF-1α. In summary, control of HIF-1α phosphorylation by ERK acts probably as a "rheostat" that determines the distribution of HIF-1α between nucleus and mitochondria and, subsequently, the balance between longterm genomic and short-term non-genomic adaptation to hypoxia. As combating the adaptation of cancer cells to hypoxia is a goal in anti-cancer therapy, targeting this mechanism may be exploited for therapeutic interventions. 
Materials and Methods
Plasmids
Protein purification and in vitro binding assays. GST-ETD and its mutant forms were
expressed in E. coli and purified as previously described for GST-HIF-1α (Chachami et al., 2005) . Approximately 10 μg of GST, GST-ETD or its mutant forms were immobilized on 25 μl glutathione-Sepharose beads and incubated with protein extracts (~1 mg of total protein) from HeLa cells lyzed with HNMT buffer (25 mM Hepes pH 7.5, 150 mM NaCl, 2 mM MgCl2, 1% Triton X-100, 0.5 mM dithiothreitol and 0.2 mM PMSF). Incubation was performed in HNMT buffer for 16 hours at 4˚C in a total volume of 0.5 ml. The beads were harvested, washed three times and proteins bound to ETD forms were eluted by incubating the beads with 50 μl of TEV protease solution (1μg diluted in Tris-HCl pH 8.0) for 16 hours at 4˚C to cleave the spacer sequence between GST and ETDs. A fraction of the eluates (5 μl) was analyzed with SDS-PAGE and visualized by AgNO3 staining or western blotting while the rest was used for analysis by mass spectroscopy.
Journal of Cell Science • Advance article
Immunoprecipitation. Immunoprecipitation experiments were performed as previously described (Mylonis et al., 2008) . Briefly, HeLa cell total extracts or fractions were incubated for 16 hours at 4˚C in HNMT buffer (25 mM Hepes pH 7.5, 150 mM NaCl, 2 mM MgCl2, 1% Triton X-100, 0.5mM dithiothreitol and 0.2 mM PMSF) with protein A beads supplemented with 1 μg of anti-HIF-1α or anti-mortalin polyclonal antibodies.
Precipitates were eluted with Laemli loading buffer and analyzed with SDS-PAGE and immunoblotting.
Reporter gene assay and real-time PCR. Reporter gene assays were performed as 
Statistical analysis. Statistical differences between two groups of data were assessed using the unpaired t-test in the GraphPad Prism version 5.04 software; P < 0.05 was considered to be significant (*P < 0.05; **P < 0.01; ***P < 0.001). Table S1 . Identification of the 75 kDa protein binding to GST-ETD-SA as mortalin. List of mortalin peptides identified after mass spectrometric analysis of the precipitatated proteins in the pull down assay perfomed with GST-ETD SA (shown in Figure 1A ). Cell Sci. 129: doi:10.1242/jcs.195339 Figure 5D (mean value of two independent experiments). In each subcellular fraction HIF-1α was normalized with the respective loading control. No comparison is possible between different fractions.
